| Original language | English (US) |
|---|---|
| Pages (from-to) | 3563-3567 |
| Number of pages | 5 |
| Journal | Blood Advances |
| Volume | 5 |
| Issue number | 18 |
| DOIs | |
| State | Published - Sep 28 2021 |
ASJC Scopus subject areas
- Hematology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Blood Advances, Vol. 5, No. 18, 28.09.2021, p. 3563-3567.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphoma
AU - Crombie, Jennifer L.
AU - Nastoupil, Loretta J.
AU - Redd, Robert
AU - Tang, Kevin
AU - Shouse, Geoffrey
AU - Herrera, Alex F.
AU - Chow, Victor A.
AU - Shadman, Mazyar
AU - Puglianini, Omar Castaneda
AU - Saucier, Anna
AU - Jacobson, Caron A.
AU - Armand, Philippe
AU - Simmons, Gary
N1 - Funding Information: Pharmacyclics, Gilead, Genentech, Abbvie, TG Therapeutics, Bei-gene, AstraZeneca, Sunesis, and Atara Biotherapeutics. C.A.J. has received consulting fees from Kite/Gilead, Novartis, BMS/Celgene, Nkarta, Precision Biosciences, Lonza, Bluebird Bio, and Abbie; research funding from Pfizer and Kite. P.A. received consulting fees from Merck, BMS, Pfizer, Affimed, Adaptive, Infinity, ADC Therapeutics, Celgene, Morphosys, Daiichi Sankyo, Miltenyi, Tessa, GenMab, C4, Enterome, Regeneron, Epizyme, Astra Zeneca, Genentech; research funding from Merck, BMS, Affimed, Adaptive, Roche, Ten-sha, Otsuka, Sigma Tau, Genentech, IGM, Kite; honoraria from Merck and BMS. The remaining authors declare no competing financial interests. Funding Information: port from Bayer and Abbvie; consulting fees from Incyte and Karyo-pharm. L.J.N. has received honorarium from ADC Therapeutics, Bayer, BMS/Celgene, Epizyme, Genentech, Janssen, KITE/Gilead, Morphosys, Novartis, Pfizer, and TG Therapeutics; research support from BMS/Celgene, Caribou, Epizyme, Genentech, Janssen, Lam Therapeutics, Novartis, Takeda, and TG Therapeutics. G. Shouse has received honoraria from Kite Pharmaceuticals. A.F.H. has received research funding from BMS, Merck, Genentech/F. Hoffmann-La Roche, Gilead Sciences, Seattle Genetics, Immune Design, AstraZe-neca, and Pharmacyclics; consultant fees from BMS, Merck, Genen-tech/F. Hoffmann-La Roche, Gilead Sciences, Seattle Genetics, and Karyopharm; and travel, accommodation, and expense compensation from BMS. V.A.C. has received research funding from AstraZeneca. M.S. reports consulting, advisory boards, steering committees, or data safety monitoring committees from Abbvie, Genentech, AstraZe-neca, Sound Biologics, Pharmacyclics, Beigene, Bristol Myers Squibb, Morphosys, TG Therapeutics, Innate Pharma, Kite Pharma, Adaptive Biotechnologies, Epizyme, and Atara Biotherapeutics; research funding from Mustang Bio, Celgene, Bristol Myers Squibb,
PY - 2021/9/28
Y1 - 2021/9/28
UR - http://www.scopus.com/inward/record.url?scp=85116383488&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85116383488&partnerID=8YFLogxK
U2 - 10.1182/bloodadvances.2021004880
DO - 10.1182/bloodadvances.2021004880
M3 - Letter
C2 - 34474474
AN - SCOPUS:85116383488
SN - 2473-9529
VL - 5
SP - 3563
EP - 3567
JO - Blood Advances
JF - Blood Advances
IS - 18
ER -